Market-Moving News for June 28th
Portfolio Pulse from Benzinga Newsdesk
Theriva Biologics' VCN-01 has been granted Orphan Drug Designation by the U.S. FDA, causing TOVX's stock to rise by 87%. Pfizer's NGENLA™, a treatment for Pediatric Growth Hormone Deficiency, has been approved by the FDA, leading to a 32% increase in OPK's stock. Meanwhile, NVDA's shares have dropped by 5% due to reports of the U.S. planning to revise its export controls on AI chips to limit China's access to advanced technologies with military applications.
June 28, 2023 | 12:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pfizer's NGENLA™, a treatment for Pediatric Growth Hormone Deficiency, has been approved by the FDA, leading to a 32% increase in OPK's stock.
The FDA's approval of NGENLA™ is a positive development for Pfizer, which is reflected in the 32% increase in OPK's stock.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Theriva Biologics' VCN-01 has been granted Orphan Drug Designation by the U.S. FDA, causing TOVX's stock to rise by 87%.
The FDA's Orphan Drug Designation for VCN-01 is a positive development for Theriva Biologics, which is reflected in the 87% increase in TOVX's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
NVDA's shares have dropped by 5% due to reports of the U.S. planning to revise its export controls on AI chips to limit China's access to advanced technologies with military applications.
The U.S.'s plans to revise its export controls on AI chips, which could limit China's access to advanced technologies with military applications, is a negative development for Nvidia, which is reflected in the 5% decrease in NVDA's stock.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100